合成,表征和辐射增强了脂质体载 (III) 复合物的抗癌活性
Shuang Tian1, Qianying Nie2, Haomin Chen1
1School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, China.
Journal of inorganic biochemistry
|April 5, 2024
概括
合成了两种新的 (III) 复合物,并对抗癌活性进行了测试. 在脂质体中封装和光激活显著提高了复合4b的有效性,通过亡和铁亡诱导癌细胞死亡.
科学领域:
- 材料科学 材料科学 材料科学
- 药用化学 医学化学
- 生物化学 生物化学
背景情况:
- (III) 复合物因其光物理性质和潜在的治疗应用而受到探索.
- 开发新型抗癌药物以提高疗效和有针对性的治疗仍然是瘤学的关键挑战.
研究的目的:
- 为了合成和描述新型的 (III) 复合物,特别是[Ir(bzq) 2[PPD] 6[PF6] 4a和[Ir(piq) 2[PPD] 6[PF6] 4b.
- 评估这些复合物的体外抗癌疗效,并探索增强其治疗潜力的策略.
- 阐明由这些复杂物及其修饰形式诱导的癌细胞死亡机制.
主要方法:
- 两种 (III) 复合物的合成和表征.
- 使用MTT进行体外细胞毒性测定,以评估对SGC-7901,A549和HepG2癌细胞系的疗效.
- 评估光照射和脂质体封装作为增强抗癌活性的策略.
- 细胞循环停止分析,细胞亡和铁亡途径调查 (MDA,GSH,GPX4水平,脂质过氧化).
- 评估线粒体膜潜力和细胞内Ca2+度.
主要成果:
- 复合物4b表现出适度的抗癌疗效,而复合物4a没有显著的活性.
- 照射光线和脂质体封装 (4alip,4blip) 都显著增强了复合物的抗癌潜力.
- 脂质体和光激活形式在S阶段诱导细胞循环停止.
- 这些复合物及其改性形式通过亡和铁亡诱导癌细胞死亡,由增加的MDA,减少的GSH,GPX4下调,脂质过氧化,减少的线粒体膜潜力和增加的细胞内Ca2+证明.
结论:
- 新型 (III) 复合物成功合成和表征.
- 脂质体封装和光激活是提高 (III) 复合物的抗癌疗效的有效策略.
- 增强的复合物通过亡和铁亡诱导癌细胞死亡,突出显示它们作为治疗剂的潜力.
相关概念视频
02:53Adaptive Mechanisms in Cancer Cells
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
02:17The Tumor Microenvironment
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:25Mutagenicity and Carcinogenicity
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.